Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SS)
CNY42.36
-0.52 (-1.21%)
CN SHH Healthcare Medical - Instruments & Supplies
Address
Changping Science & Technology Park
Beijing, CN
Beijing, CN
CEO
Jiangbing Xie
Website
ebmedical.com
IPO
2020-07-29
ISIN CNE1000041J5
Description
Eye Bright Medical Technology Co., Ltd., established in 2010 in Beijing, China, specializes in crafting a diverse array of ophthalmic medical solutions. The company's extensive product line is geared towards addressing various ocular conditions and visual impairments, encompassing surgical implants, specialized instruments, and diagnostic equipment, as well as optometric lenses and pharmaceutical eye drops. These innovations are developed to provide treatment for a range of eye diseases, notably cataracts, glaucoma, and refractive errors, among other ophthalmic issues.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY42.36
-0.52 (-1.21%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
0.35
Float Shares
142.48M
Free Float %
73.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.09% | -7.18% | -17.29% | -31.95% | -30.15% | -30.07% | -40.60% | -63.78% | -77.48% | -82.36% | -82.36% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
42.36
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.22
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Instruments & Supplies: +7.9%+5.2% Q1'26: +11.5% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-31.7% Q1'26: -6.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+3.6% Q1'26: -3.2% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+19.5% ★ Q1'26: +26.2% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+9.4% ★ Q1'26: +10.8% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+1.5% Q1'26: +2.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.90× ★ Q1'26: 2.35× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 5 EPS Ana. |
Dec 2027 6 Rev. Ana. 6 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
273.05M
est: 277.08M (-1.5%)
|
433.07M
est: 437.27M (-1.0%)
|
579.50M
est: 585.57M (-1.0%)
|
951.18M
est: 1.23B (-22.7%)
|
1.41B
est: 1.41B (+0.2%)
|
1.48B
est: 1.56B (-5.0%)
|
1.80B
1.64B – 1.87B
+15.1% YoY
|
2.08B
1.88B – 2.27B
+16.0% YoY
|
2.38B
2.34B – 2.41B
+14.0% YoY
|
| EBITDA |
137.76M
est: 119.53M (+15.3%)
|
218.78M
est: 188.64M (+16.0%)
|
305.99M
est: 252.61M (+21.1%)
|
410.01M
est: 530.75M (-22.7%)
|
580.20M
est: 607.06M (-4.4%)
|
417.66M
est: 673.72M (-38.0%)
|
775.56M
708.00M – 805.64M
+15.1% YoY
|
899.33M
812.91M – 978.20M
+16.0% YoY
|
1.03B
1.01B – 1.04B
+14.0% YoY
|
| EBIT |
111.10M
est: 97.20M (+14.3%)
|
188.60M
est: 153.40M (+22.9%)
|
266.20M
est: 205.42M (+29.6%)
|
337.65M
est: 434.38M (-22.3%)
|
452.06M
est: 496.84M (-9.0%)
|
289.52M
est: 551.39M (-47.5%)
|
634.74M
579.45M – 659.36M
+15.1% YoY
|
736.03M
665.31M – 800.58M
+16.0% YoY
|
838.91M
826.14M – 851.67M
+14.0% YoY
|
| Net Income |
96.56M
est: 104.21M (-7.3%)
|
171.34M
est: 169.35M (+1.2%)
|
232.69M
est: 232.34M (+0.2%)
|
303.98M
est: 348.84M (-12.9%)
|
388.40M
est: 393.67M (-1.3%)
|
268.17M
est: 334.58M (-19.8%)
|
400.57M
380.81M – 442.50M
+19.7% YoY
|
494.81M
447.55M – 532.52M
+23.5% YoY
|
570.74M
521.21M – 607.76M
+15.3% YoY
|
| SGA |
96.03M
est: 86.31M (+11.3%)
|
142.27M
est: 136.21M (+4.4%)
|
176.50M
est: 182.41M (-3.2%)
|
295.24M
est: 330.84M (-10.8%)
|
369.89M
est: 378.41M (-2.3%)
|
206.11M
est: 419.97M (-50.9%)
|
483.45M
441.33M – 502.20M
+15.1% YoY
|
560.60M
506.73M – 609.76M
+16.0% YoY
|
638.95M
629.23M – 648.68M
+14.0% YoY
|
| EPS |
0.60
est: 0.55 (+9.1%)
|
0.91
est: 0.89 (+1.8%)
|
1.23
est: 1.23 (+0.3%)
|
1.61
est: 1.85 (-12.8%)
|
2.05
est: 2.06 (-0.3%)
|
1.40
est: 1.77 (-20.9%)
|
2.13
1.98 – 2.30
+20.1% YoY
|
2.54
2.33 – 2.77
+19.4% YoY
|
3.00
2.71 – 3.16
+18.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-07 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-06 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-30 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-29 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
343.19M
OE per share TTM
1.79
Owner's Yield
4.17%
Maintenance CapEx ratio
16.77%
Maint CapEx / Avg PPE
113.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 21 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 143.8K | 0.39% |
| 2 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 111.2K | 0.29% |
| 3 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 91.6K | 0.06% |
| 4 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 22.4K | 0.26% |
| 5 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 9.9K | 0.48% |
| 6 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.10M | 0.06% |
| 7 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.00% | 29.2K | 0.17% |
| 8 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 29.2K | 0.17% |
| 9 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 33.4K | 0.28% |
| 10 | Vanguard ESG International Stock ETF VSGX | 0.00% | 14.1K | 0.10% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
139.6K
Shares Outstanding
193.40M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Baoshan Jia | Deputy GM, National Marketing & Sales Director | — | male |
| Danxuan Wang | Chairperson of the Supervisory Board & Senior Human Resources Manager | — | female |
| Jiangbing Xie | Chairman of the Board, GM & Chief Scientist | — | male |
| Jie Yu | R&D Project Manager | — | female |
| Shaohua Wang | Senior Vice President, Director of Operations & Director | — | female |
| Shuyan Guo | R&D Project Manager | — | female |
| Yanchang Guo | Deputy GM, Chief Financial Officer, Financial Director & Accounting Supervisor | — | male |
| Yuqian Zhou | Assistant to the GM & Board Secretary | — | female |
| Zhao Wang | Deputy GM, R&D Director & Director | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688050.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
